Abstract
The pharmacology, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, dosage and administration, and place in therapy of rilpivirine are reviewed. Rilpivirine is a human immunodeficiency virus type 1 (HIV-1)-specific nonnucleoside reverse transcriptase inhibitor (NNRTI) indicated for use in combination with other antiretroviral agents in adult patients not previously treated with antiretroviral therapy. Rilpivirine is primarily metabolized by the cytochrome P-450 (CYP)3A isoenzyme system. Therefore, providers should be cautious when administering drugs that are inhibitors or inducers of this pathway. Coadministration with CYP 3A inhibitors may lead to increased concentrations of rilpivirine, thereby increasing the risk of adverse effects. Coadministration with inducers of CYP3A isoenzymes or drugs that increase gastric pH may lead to decreased concentrations of rilpivirine, thus promoting virological failure or resistance to rilpivirine. Two Phase III, randomized, double-blind, double-dummy, active-controlled trials compared rilpivirine with efavirenz in HIV-infected adults not previously treated with an antiretroviral. The investigators concluded that rilpivirine, when combined with two nucleoside or nucle...Continue Reading
References
Mar 27, 1998·The New England Journal of Medicine·F J PalellaS D Holmberg
Oct 9, 2001·HIV Clinical Trials·UNKNOWN Panel on Clinical Practices for Treatment of HIV Infection
Mar 18, 2005·Journal of Medicinal Chemistry·Paul A J JanssenPaul Stoffels
May 7, 2005·The Pediatric Infectious Disease Journal·Susan SchuvalUNKNOWN Pediatric AIDS Clinical Trials Group Protocol 1028S Team
May 10, 2005·Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology·J C F Van HeeswijkG E E J M Van den Thillart
Jun 9, 2005·European Neurology·Asako YoritakaShuji Kishida
Aug 26, 2006·AIDS·Frank GoebelBrian Woodfall
May 8, 2008·British Journal of Clinical Pharmacology·Vanitha J SekarRichard M Hoetelmans
Nov 21, 2009·AIDS·Anton L PozniakUNKNOWN TMC278-C204 Study Group
Dec 15, 2010·Clinical Pharmacokinetics·Thomas N KakudaRichard M W Hoetelmans
May 17, 2011·Vaccine·Christoph HatzChristian Herzog
Jul 19, 2011·Lancet·Calvin J CohenUNKNOWN THRIVE study group
Jul 19, 2011·Lancet·Jean-Michel MolinaUNKNOWN ECHO study group
Jul 20, 2011·Antiviral Research·Si-Nafa Si-AhmedFabien Zoulim
Citations
Apr 17, 2014·Tree Physiology·Jean-Sébastien JacquetHervé Jactel
Feb 18, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R PalaciosJ Santos
Mar 18, 2015·HIV Clinical Trials·Sheng-Li LiZhao-Jun Lu
Dec 1, 2014·HIV Clinical Trials·Sheng-Li LiZhao-Jun Lu
Apr 28, 2016·PloS One·Phairote TeeranaipongOpass Putcharoen
Jul 23, 2019·Expert Opinion on Drug Delivery·Yuqing GongSantosh Kumar
Feb 6, 2020·Therapeutic Drug Monitoring·Funda InanEric J F Franssen
Nov 18, 2020·Journal of Dietary Supplements·Mona H HaronShabana I Khan PhD
Oct 25, 2013·Journal of the American Chemical Society·Won-Gil LeeWilliam L Jorgensen
Feb 24, 2015·Journal of Medicinal Chemistry·Kathleen M FreyKaren S Anderson